Skip to main content
Fig. 6 | Clinical and Translational Allergy

Fig. 6

From: Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months

Fig. 6

Unsupervised hierarchical clustering of protein lists obtained by analyzing lung biopsies from omalizumab responders (OR, blue) and non-omalizumab responders (NOR, red). a Before (baseline). b After 36 months of anti-IgE treatment. The clusters obtained were based on SEQUEST score value and proved to be well structured (agglomerative coefficients >0.7). OR and NOR are classified according to whether they experienced a reduction in RBM thickness (OR) or no reduction in RBM thickness (NOR) after 12 months of anti-IgE treatment

Back to article page